Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMX-110 in advanced solid tumors
NCT03382340Phase 2Active, not recruiting
- Sponsor
- Immix Biopharma
- Start
- Feb 2018
- Primary completion
- Oct 2023
- Modality
- Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of IMX-110 in solid tumor (advanced stage), pancreatic cancer (PC), breast cancer, ovarian cancer, sponsored by Immix Biopharma. Started Feb 2018; status: active, not recruiting.
02
Drugs
IMX-110
03
Conditions
solid tumor (advanced stage)pancreatic cancer (PC)breast cancerovarian cancer
Beyond the preview
Go deeper on NCT03382340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03382340.